News

The Phase I clinical trial of VIA-3196 will assess the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The company expects to recruit around 72 patients in

RXT 110 has agreed to make payments aggregating to $150,000 over the course of the next four months for an interim license. During the term of the interim

The trial is intended to evaluate the safety, bioactivity and anti-tumor effect of patients’ own T cells that have been genetically modified to express a high affinity T

ALS-2200 and ALS-2158, currently in preclinical development, are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. As part of the

The Phase I trial is expected to assess safety along with the immunological and biological effects of ZIN ATI-001 in patients with melanoma. ZIN ATI-001 employs an adenoviral

Merck’s Label Standardization Project includes evaluating the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. The Label

The tie up allows Pall to use the services of Avacta and market joint services in North America, and in other regions globally where Avacta is not currently

Following the investment by Quintiles, Kareus plans to submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity discovered by Kareus for the treatment

VX-770 is a medicine in development for people with cystic fibrosis who are 6 years or older and have at least one copy of the G551D mutation. The